These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 9135876)
1. Characterization and titration of an HIV type 1 subtype E chimpanzee challenge stock. Barré-Sinoussi F; Georges-Courbot MC; Fultz PN; Nguyen Thi Tuyet H; Muchmore E; Saragosti S; Dubreuil G; Georges A; van der Ryst E; Girard M AIDS Res Hum Retroviruses; 1997 May; 13(7):583-91. PubMed ID: 9135876 [TBL] [Abstract][Full Text] [Related]
2. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. Robert-Guroff M; Kaur H; Patterson LJ; Leno M; Conley AJ; McKenna PM; Markham PD; Richardson E; Aldrich K; Arora K; Murty L; Carter L; Zolla-Pazner S; Sinangil F J Virol; 1998 Dec; 72(12):10275-80. PubMed ID: 9811775 [TBL] [Abstract][Full Text] [Related]
3. Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees. Murthy KK; Cobb EK; el-Amad Z; Ortega H; Hsueh FC; Satterfield W; Lee DR; Kalish ML; Haigwood NL; Kennedy RC; Steimer KS; Schultz A; Levy JA AIDS Res Hum Retroviruses; 1996 Sep; 12(14):1341-8. PubMed ID: 8891113 [TBL] [Abstract][Full Text] [Related]
5. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection. Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990 [TBL] [Abstract][Full Text] [Related]
6. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. De Wolf F; Hogervorst E; Goudsmit J; Fenyö EM; Rübsamen-Waigmann H; Holmes H; Galvao-Castro B; Karita E; Wasi C; Sempala SD AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1387-400. PubMed ID: 7888192 [TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a full-length infectious clone from a fast-replicating, X4-tropic HIV-1 subtype B' isolate. Wu SL; Yan YS; Yan PP; Huang HL; Wang HR Arch Virol; 2010 Dec; 155(12):1923-31. PubMed ID: 20697919 [TBL] [Abstract][Full Text] [Related]
8. The inability of human immunodeficiency virus to infect chimpanzee monocytes can be overcome by serial viral passage in vivo. Gendelman HE; Ehrlich GD; Baca LM; Conley S; Ribas J; Kalter DC; Meltzer MS; Poiesz BJ; Nara P J Virol; 1991 Jul; 65(7):3853-63. PubMed ID: 1674968 [TBL] [Abstract][Full Text] [Related]
9. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. Beaumont T; Broersen S; van Nuenen A; Huisman HG; de Roda Husman AM; Heeney JL; Schuitemaker H J Virol; 2000 Sep; 74(17):7699-707. PubMed ID: 10933675 [TBL] [Abstract][Full Text] [Related]
10. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism. Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846 [TBL] [Abstract][Full Text] [Related]
11. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Harrowe G; Cheng-Mayer C Virology; 1995 Jul; 210(2):490-4. PubMed ID: 7618285 [TBL] [Abstract][Full Text] [Related]
12. Infection of chimpanzee peripheral blood mononuclear cells by human immunodeficiency virus type 1 requires cooperative interaction between multiple variable regions of gp120. Cho MW; Shibata R; Martin MA J Virol; 1996 Oct; 70(10):7318-21. PubMed ID: 8794390 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Abebe A; Demissie D; Goudsmit J; Brouwer M; Kuiken CL; Pollakis G; Schuitemaker H; Fontanet AL; Rinke de Wit TF AIDS; 1999 Jul; 13(11):1305-11. PubMed ID: 10449282 [TBL] [Abstract][Full Text] [Related]
14. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions. Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113 [TBL] [Abstract][Full Text] [Related]
15. Relationship between V3 genotype, biologic phenotype, tropism, and coreceptor use for primary isolates of human immunodeficiency virus type 1. McDonald RA; Chang G; Michael NL J Hum Virol; 2001; 4(4):179-87. PubMed ID: 11694845 [TBL] [Abstract][Full Text] [Related]
17. Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro. Moog C; Spenlehauer C; Fleury H; Heshmati F; Saragosti S; Letourneur F; Kirn A; Aubertin AM AIDS Res Hum Retroviruses; 1997 Jan; 13(1):19-27. PubMed ID: 8989423 [TBL] [Abstract][Full Text] [Related]
18. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda. Bruce C; Clegg C; Featherstone A; Smith J; Biryahawaho B; Downing R; Oram J AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1543-50. PubMed ID: 7888209 [TBL] [Abstract][Full Text] [Related]
19. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2. el-Amad Z; Murthy KK; Higgins K; Cobb EK; Haigwood NL; Levy JA; Steimer KS AIDS; 1995 Dec; 9(12):1313-22. PubMed ID: 8605050 [TBL] [Abstract][Full Text] [Related]
20. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. Watanabe M; Ringler DJ; Fultz PN; MacKey JJ; Boyson JE; Levine CG; Letvin NL J Virol; 1991 Jun; 65(6):3344-8. PubMed ID: 1674550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]